116.49
-2.12(-1.79%)
Currency In USD
| Previous Close | 118.61 |
| Open | 117.97 |
| Day High | 118.61 |
| Day Low | 115.5 |
| 52-Week High | 238 |
| 52-Week Low | 110.04 |
| Volume | 1.72M |
| Average Volume | 1.73M |
| Market Cap | 17.05B |
| PE | 10.42 |
| EPS | 11.18 |
| Moving Average 50 Days | 135.28 |
| Moving Average 200 Days | 169.93 |
| Change | -2.12 |
If you invested $1000 in Biogen Inc. (BIIB) 10 years ago, it would be worth $275.02 as of April 22, 2025 at a share price of $116.49. Whereas If you bought $1000 worth of Biogen Inc. (BIIB) shares 5 years ago, it would be worth $390.89 as of April 22, 2025 at a share price of $116.49.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
GlobeNewswire Inc.
Apr 02, 2025 11:30 AM GMT
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide (ASO) thera
Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square
GlobeNewswire Inc.
Mar 24, 2025 11:30 AM GMT
Biogen signs lease for Kendall Common as part of multi-year real estate optimization plan to modernize its facilities and consolidate its Massachusetts real estate footprintNew building will be designed to foster collaboration and spark innovation; B
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
GlobeNewswire Inc.
Mar 11, 2025 11:30 AM GMT
Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a leading cause of kidney transplant loss, with approximately ~23k patients living with all forms of AMR in the